Phospho-MAPK15 (T175/Y177) Antibody

What is the significance of T175/Y177 phosphorylation in MAPK15 function?

Phosphorylation at threonine 175 and tyrosine 177 residues is a critical post-translational modification that activates the MAPK15 enzyme. This dual phosphorylation is essential for MAPK15's kinase activity and its subsequent ability to regulate downstream cellular processes. Research has shown that this activation is autophosphorylation-dependent, meaning MAPK15 can phosphorylate itself at these residues .

The functional significance of this phosphorylation includes:

• Activation of kinase activity required for phosphorylation of downstream targets such as FOS and MBP in vitro

• Enabling interaction with PCNA to protect genomic integrity

• Facilitating MAPK15's role in autophagy regulation through interactions with GABARAP, MAP1LC3B, and GABARAPL1

• Supporting mitophagy processes that protect cells from oxidative stress-induced damage

Without phosphorylation at T175/Y177, MAPK15 remains in an inactive state, unable to perform its diverse cellular functions. Interestingly, while some functions of MAPK15 are kinase activity-dependent (requiring phosphorylation), others function in a kinase activity-independent manner, such as its role as a negative regulator of growth .

How can researchers validate the specificity of Phospho-MAPK15 (T175/Y177) antibodies?

Recommended validation methodology:

• Peptide competition assays: Pre-incubate the antibody with the immunogen phospho-peptide before application. This should abolish specific signals in immunoblotting or immunohistochemistry applications .

• Phosphatase treatment: Treat one sample with lambda phosphatase to remove phosphorylation, which should eliminate signal when compared to untreated controls .

• Genetic manipulation: Use MAPK15 knockdown (siRNA) or knockout models as negative controls .

• Stimulus-response validation: Treat cells with stimuli known to induce MAPK15 phosphorylation (such as H₂O₂ or TNF-α) and observe increased antibody signal .

• Cross-reactivity testing: Test against closely related MAP kinases to ensure specificity .

Immunohistochemical validation has shown specific staining in human brain tissue sections, with signals abolished when the antibody was pre-absorbed by immunogen peptide, confirming specificity .

What are the optimal experimental conditions for using Phospho-MAPK15 (T175/Y177) antibodies?

Successful application of Phospho-MAPK15 (T175/Y177) antibodies requires optimization of several experimental parameters based on the specific application:

Western Blot (WB) Conditions:

• Recommended dilution range: 1:500-1:2000

• Sample preparation: Use of nuclear extraction methods can enhance detection, as shown with successful results using Minute™ Cytoplasmic and Nuclear Fractionation kit for Jurkat cell analysis

• Blocking: 5% BSA in TBST is preferable to milk for phospho-epitopes

• Detection systems: ECL-based or fluorescent secondary antibodies both work effectively

Immunohistochemistry (IHC) Conditions:

• Recommended dilution: 1:100-1:300

• Antigen retrieval: High-pressure and temperature Tris-EDTA, pH 8.0 has been validated for human brain tissue sections

• Incubation: 4°C overnight incubation shows optimal results

• Detection: DAB visualization with hematoxylin counterstain

Immunofluorescence (IF) Conditions:

• Recommended dilution: 1:50-1:200

• Fixation: Methanol fixation has been validated with A431 cells

• Cell types successfully tested: A431 and HeLa cells

For all applications, storing the antibody at -20°C for long-term storage (up to 1 year) and at 4°C for short-term use (up to one month) is recommended. Repeated freeze-thaw cycles should be avoided to maintain antibody integrity and performance .

How can Phospho-MAPK15 (T175/Y177) antibodies be utilized to study the role of MAPK15 in mitophagy and cellular senescence?

Recent research has established MAPK15's critical role in mitophagy—the selective autophagy of damaged mitochondria—which protects cells from oxidative stress-induced senescence. Phospho-MAPK15 antibodies provide valuable tools for investigating these processes through several advanced methodological approaches:

Mitophagy assessment methodology:

• Co-localization studies: Implement dual immunofluorescence staining with Phospho-MAPK15 (T175/Y177) antibodies and mitochondrial markers (TOMM20, COX IV) to visualize active MAPK15 recruitment to damaged mitochondria .

• Mitophagy flux assays: Combine Phospho-MAPK15 immunoblotting with mitophagy markers including PINK1, Parkin (PRKN), and mitochondrial mass indicators to correlate MAPK15 activation with mitophagy progression .

• ULK1-PRKN pathway analysis: Use Phospho-MAPK15 antibodies in conjunction with phospho-specific antibodies against ULK1 and PRKN Ser108 to elucidate the sequential activation pattern during mitophagy .

• Functional rescue experiments: In MAPK15-knockdown cells showing increased ROS and reduced mitophagy, restoration experiments with wild-type versus T175A/Y177F phospho-deficient mutants can determine phosphorylation dependency .

Research has demonstrated that reduced MAPK15 expression strongly decreases mitochondrial respiration and ATP production while increasing mitochondrial ROS levels. MAPK15 controls mitophagy by stimulating ULK1-dependent PRKN Ser108 phosphorylation and inducing recruitment of damaged mitochondria to autophagosomal and lysosomal compartments .

A comprehensive experimental approach should include assessment of:

• Mitochondrial membrane potential (ΔΨm)

• Mitochondrial ROS production

• ATP generation capacity

• Mitochondrial network reorganization

• Nuclear DNA damage markers (γH2AX)

• Senescence markers (SA-β-galactosidase, p16INK4a, p21)

This integrated methodology allows researchers to establish the causal relationship between MAPK15 phosphorylation status, mitophagy efficiency, and cellular senescence protection.

What experimental approaches can reveal the relationship between TNF-α/NF-κB signaling and MAPK15 phosphorylation in chemosensitivity?

Research has established a complex bidirectional relationship between MAPK15 and NF-κB signaling, with significant implications for cancer chemosensitivity. Several experimental approaches using Phospho-MAPK15 (T175/Y177) antibodies can elucidate these interactions:

Methodological framework:

• ChIP-qPCR assays: Chromatin immunoprecipitation followed by qPCR targeting the MAPK15 promoter TBS4 (transcription binding site 4) can quantify NF-κB p65 binding following TNF-α stimulation .

• Promoter-luciferase reporter assays: Using MAPK15 promoter constructs (wild-type vs. TBS4-mutated) to measure transcriptional activation following TNF-α treatment .

• Time-course phosphorylation analysis: Western blotting with Phospho-MAPK15 (T175/Y177) antibodies following TNF-α treatment reveals the temporal dynamics of MAPK15 activation .

• Co-treatment chemosensitivity studies: Measure apoptosis markers (cleaved caspase-3, cleaved PARP1) in cells treated with TNF-α plus cisplatin, comparing MAPK15-knockdown vs. control cells .

• In vivo tumor xenograft models: Assess tumor response to cisplatin ± TNF-α in animals implanted with MAPK15-overexpressing vs. control cancer cells .

Research findings have revealed that TNF-α enhances cisplatin sensitivity through MAPK15. The experimental data shows TNF-α activates NF-κB signaling, which binds to the MAPK15 promoter at TBS4, inducing MAPK15 expression. Elevated MAPK15 levels enhance cisplatin sensitivity by affecting DNA repair capacity in cisplatin-treated cells .

This research framework establishes MAPK15 as a critical determinant of cisplatin responsiveness in lung cancer, with TNF-α-mediated upregulation offering a potential strategy to improve therapeutic efficacy .

How does MAPK15 phosphorylation status correlate with its subcellular localization and function?

MAPK15 exhibits dynamic subcellular localization patterns that correlate with its phosphorylation status and dictate its diverse cellular functions. Investigating this relationship requires sophisticated experimental approaches using Phospho-MAPK15 (T175/Y177) antibodies:

Methodological approaches:

• Subcellular fractionation followed by immunoblotting: Separate nuclear, cytoplasmic, mitochondrial, Golgi, and autophagosomal fractions to quantify the relative distribution of phosphorylated versus total MAPK15 .

• Multi-color immunofluorescence microscopy: Co-stain cells with Phospho-MAPK15 (T175/Y177) antibodies and organelle markers under various cellular conditions (starvation, oxidative stress, mitotic stages) to track dynamic relocalization .

• Proximity ligation assays (PLA): Use PLA to detect interactions between phospho-MAPK15 and compartment-specific binding partners like GABARAP (autophagosomes), PCNA (nucleus), or ESRRA (cytoplasm-nucleus shuttle) .

• Live-cell imaging with phospho-mimetic mutations: Compare subcellular dynamics of GFP-tagged MAPK15-T175D/Y177E (phospho-mimetic) versus T175A/Y177F (phospho-deficient) mutants .

Research has revealed several critical localization-function relationships:

• Phosphorylated MAPK15 translocates to the nucleus upon activation, where it interacts with PCNA to protect genomic integrity by inhibiting MDM2-mediated PCNA degradation

• During mitosis, phosphorylated MAPK15 localizes to the spindle at various stages including prometaphase I, metaphase I, anaphase I, telophase I, and metaphase II

• Upon autophagy induction, phospho-MAPK15 associates with autophagosomal markers and mediates interactions with GABARAP, MAP1LC3B, and GABARAPL1

• In response to H₂O₂ treatment, phosphorylated MAPK15 interacts with and phosphorylates ELAVL1, affecting its RNA-binding capabilities

• At cell junctions, particularly tight junctions, MAPK15 regulates ciliogenesis and ciliary protein localization

These diverse localizations explain MAPK15's multifunctional nature and highlight the importance of phosphorylation in determining its spatial distribution and subsequent functional outcomes.

What methodologies are optimal for studying MAPK15 as a potential therapeutic target in age-associated diseases?

MAPK15's emerging role in protecting against cellular senescence, particularly through mitophagy regulation, positions it as a promising therapeutic target for age-associated diseases. Several methodological approaches using Phospho-MAPK15 (T175/Y177) antibodies can advance this research area:

Comprehensive research framework:

• Primary cell senescence models: Employ Phospho-MAPK15 antibodies to track MAPK15 activation status during replicative or stress-induced senescence in primary human airway epithelial cells, fibroblasts, and other tissue-specific cells relevant to age-associated diseases .

• High-content screening platforms: Develop cell-based assays using Phospho-MAPK15 immunostaining to screen compound libraries for molecules that enhance MAPK15 phosphorylation and activity, potentially identifying senescence-protective agents .

• Patient-derived sample analysis: Immunohistochemistry with Phospho-MAPK15 antibodies on tissue biopsies from patients with age-associated diseases versus age-matched controls to establish correlations between phospho-MAPK15 levels and disease phenotypes .

• Preclinical animal models: Utilize Phospho-MAPK15 antibodies to monitor therapeutic interventions targeting MAPK15 pathways in transgenic mouse models of accelerated aging or age-associated diseases .

• Multi-omics integration: Combine phospho-specific immunoprecipitation of MAPK15 with proteomics and transcriptomics to identify networks affected by MAPK15 activity in the context of aging .

Research has demonstrated that MAPK15 protects primary human airway epithelial cells from senescence by preserving mitochondrial quality through efficient disposal of damaged organelles. This suggests MAPK15 as a potential therapeutic target in diverse age-associated human diseases .

Key research findings indicate that mitochondrial dysfunction and the resulting oxidative stress contribute significantly to aging and neurodegenerative disorders. MAPK15's regulatory role in mitophagy presents a mechanism to counteract these pathological processes by:

• Maintaining mitochondrial respiration and ATP production

• Reducing mitochondrial ROS levels

• Preventing accumulation of nuclear DNA damage

• Protecting against senescence derived from chronic DNA insult

This research direction holds particular promise for neurodegenerative conditions, where mitochondrial dysfunction is a hallmark feature, and enhancement of mitophagy represents a therapeutic strategy with broad potential applications.

How can researchers optimize detection of T175/Y177 dual phosphorylation in low-abundance samples?

Detecting phosphorylated MAPK15 in low-abundance samples presents technical challenges that require optimization of sample preparation and detection methods. Several advanced approaches can enhance sensitivity:

Enhanced detection methodology:

• Phospho-enrichment techniques: Implement titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC) to concentrate phosphorylated proteins prior to immunoblotting with Phospho-MAPK15 antibodies .

• Nuclear extraction protocols: Since MAPK15 translocates to the nucleus upon activation, nuclear fractionation (using systems like Minute™ Cytoplasmic and Nuclear Fractionation kit) can concentrate the phosphorylated protein for improved detection .

• Signal amplification systems: Employ tyramide signal amplification (TSA) for immunohistochemistry or amplified chemiluminescence systems for Western blotting to enhance detection sensitivity .

• Phosphatase inhibitor optimization: Use a comprehensive cocktail of phosphatase inhibitors during sample preparation, including sodium fluoride, sodium pyrophosphate, sodium orthovanadate, and β-glycerophosphate to preserve phosphorylation status .

• Alternative sample loading controls: For tissues or cells with variable total MAPK15 expression, normalize phospho-MAPK15 signals to total MAPK15 rather than housekeeping proteins to obtain a true measure of phosphorylation status .

Research has shown that phospho-MAPK15 detection can be optimized in Western blotting applications using dilutions between 1:500-1:2000, with nuclear extracted samples providing clearer results in cell lines like Jurkat . For immunohistochemistry applications, high-pressure and temperature Tris-EDTA (pH 8.0) antigen retrieval followed by overnight antibody incubation at 4°C yields optimal staining results .

When sample quantity is severely limited, micro-Western arrays or capillary-based immunoassay systems can provide enhanced sensitivity while requiring significantly less sample input compared to traditional Western blotting techniques.

What are the best strategies for differentiating between MAPK15-specific and off-target effects in functional studies?

Establishing MAPK15-specific effects versus off-target effects is crucial for accurate interpretation of experimental results. Several complementary approaches can help researchers make this distinction:

Methodological strategies:

• Multiple knockdown/knockout systems: Implement different genetic approaches (siRNA, shRNA, CRISPR/Cas9) targeting MAPK15 and confirm consistent phenotypes across these systems .

• Rescue experiments with phospho-variants: Reintroduce wild-type MAPK15, kinase-dead mutants, or phospho-site mutants (T175A/Y177F) to MAPK15-depleted cells and assess which constructs restore function .

• Pharmacological specificity testing: When using MAPK pathway inhibitors, include control experiments with inhibitors of related pathways (JNK, MEK1/2, p38) to confirm MAPK15-specific effects .

• Domain swapping experiments: Create chimeric proteins with catalytic domains from related MAP kinases to pinpoint functional specificity to particular protein domains .

• Parallel substrate validation: Verify putative MAPK15-dependent phosphorylation events by in vitro kinase assays with recombinant MAPK15 and by in vivo phospho-specific antibodies against the substrate .

Research findings from gastric cancer studies demonstrate the importance of such controls—MAPK15 was found to promote c-Jun phosphorylation independent of JNK, MEK1/2, and p38 MAPK pathways, establishing a MAPK15-specific effect that could have been misattributed without proper controls .

Careful experimental design with appropriate controls is essential, particularly when investigating pathways with potential redundancy among related kinases or when using partially selective pharmacological agents.

How is MAPK15 phosphorylation involved in cancer chemoresistance mechanisms?

MAPK15 phosphorylation has emerged as a critical factor in cancer chemosensitivity, particularly for platinum-based therapies. Understanding this relationship requires sophisticated experimental approaches using phospho-specific antibodies:

Research methodologies:

• Paired chemosensitive/resistant cell line analyses: Compare Phospho-MAPK15 (T175/Y177) levels between parental chemosensitive and derived chemoresistant cancer cell lines using quantitative immunoblotting .

• Clinical sample correlation studies: Analyze phospho-MAPK15 levels in patient tumor samples pre- and post-chemotherapy using immunohistochemistry, correlating with treatment response .

• DNA repair capacity assays: Investigate the relationship between MAPK15 phosphorylation status and platinum-DNA adduct repair efficiency using comet assays and γH2AX foci formation in MAPK15-manipulated cells .

• Copy number variation analysis: Correlate MAPK15 gene copy number (assessed by aCGH) with phospho-MAPK15 protein levels and chemotherapy response in cancer tissues .

Research findings have revealed that MAPK15 expression levels positively correlate with cisplatin sensitivity in non-small cell lung cancer, with TNF-α enhancing this sensitivity through upregulation of MAPK15 . The mechanism involves MAPK15 affecting the DNA repair capacity of cisplatin-treated cells, where higher phospho-MAPK15 levels correlate with increased cisplatin-induced apoptosis .

In gastric cancer, copy number gains of MAPK15 were found in 17% (15/88) of tumor tissues, with mRNA levels of MAPK15 relatively higher in tissues with copy number gains compared to those without . Knockdown of MAPK15 in gastric cancer cells significantly suppressed cell proliferation and resulted in cell cycle arrest at G1-S phase, suggesting potential therapeutic implications .

These findings position MAPK15 as a potential biomarker for chemotherapy response and a target for enhancing chemosensitivity in resistant tumors, particularly when combined with TNF-α pathway activation.

What is the relationship between MAPK15 phosphorylation and autophagy regulation during different cellular stresses?

MAPK15 plays a multifaceted role in autophagy regulation, with its phosphorylation status serving as a key determinant of its function under various cellular stresses. Investigating this relationship requires specialized methodologies:

Research approaches:

• Stress-specific phosphorylation profiling: Use Phospho-MAPK15 (T175/Y177) antibodies to track MAPK15 activation patterns under distinct stressors (nutrient starvation, oxidative stress, ER stress, hypoxia) with temporal resolution .

• Autophagy flux assessment: Combine LC3-II conversion assays and p62/SQSTM1 degradation monitoring with phospho-MAPK15 status to correlate MAPK15 activation with autophagy progression under different stresses .

• Selective autophagy differentiation: Implement co-immunoprecipitation of phospho-MAPK15 with markers of different selective autophagy pathways (mitophagy: PINK1/Parkin; aggrephagy: p62/SQSTM1; ER-phagy: FAM134B) to determine stress-specific interactions .

• MAPK15-interactome mapping: Use proximity-dependent biotin identification (BioID) with wild-type versus phospho-site mutant MAPK15 to identify phosphorylation-dependent protein interactions under various stress conditions .

Research has established that MAPK15 controls both basal and starvation-induced autophagy through its interaction with GABARAP, MAP1LC3B, and GABARAPL1, leading to autophagosome formation, SQSTM1 degradation, and reduced MAP1LC3B inhibitory phosphorylation . During amino acid starvation specifically, MAPK15 mediates transitional endoplasmic reticulum site disassembly and inhibition of secretion .

In the context of oxidative stress, MAPK15 has been shown to protect cells from accumulating nuclear DNA damage due to mitochondrial ROS by controlling mitophagy . This process involves MAPK15-dependent stimulation of ULK1-dependent PRKN Ser108 phosphorylation and recruitment of damaged mitochondria to autophagosomal and lysosomal compartments .

The dual role of MAPK15 in both general and selective autophagy highlights its position as a central coordinator of cellular stress responses, with its phosphorylation status serving as a molecular switch that dictates specific pathway activation based on the nature of the cellular stressor.

How might targeting MAPK15 phosphorylation be developed as a therapeutic strategy in age-associated diseases?

MAPK15's role in protecting against cellular senescence through mitophagy regulation presents a promising therapeutic avenue for age-associated diseases. Several research approaches can advance this potential:

Translational research framework:

• Phosphorylation-enhancing small molecules: Develop high-throughput screening assays using Phospho-MAPK15 (T175/Y177) antibodies to identify compounds that enhance MAPK15 phosphorylation without affecting total protein levels .

• Pathway-specific activation strategies: Investigate NF-κB pathway modulators like TNF-α that upregulate MAPK15 expression and subsequently increase phospho-MAPK15 levels for therapeutic potential in senescence-related conditions .

• Phosphatase inhibition approach: Identify and target specific phosphatases that dephosphorylate MAPK15 at T175/Y177 to prolong its active state and enhance mitophagy in models of age-associated diseases .

• Tissue-specific delivery systems: Develop methodologies for targeting MAPK15-activating agents to specific tissues particularly vulnerable to age-related mitochondrial dysfunction, such as neurons, cardiomyocytes, or skeletal muscle .

• Biomarker development: Utilize Phospho-MAPK15 antibodies to establish circulating or tissue-based biomarkers that predict mitophagy capacity and cellular senescence susceptibility .

Research has demonstrated that MAPK15 protects primary human airway epithelial cells from senescence, establishing a specific role for MAPK15 in controlling mitochondrial fitness through efficient disposal of damaged organelles . This suggests MAPK15 as a potential therapeutic target in diverse age-associated human diseases, particularly those with mitochondrial dysfunction components like neurodegenerative disorders .

The therapeutic potential is supported by experimental evidence showing that reduced MAPK15 expression strongly decreases mitochondrial respiration and ATP production while increasing mitochondrial ROS levels, which are hallmarks of aging tissues . Conversely, enhanced MAPK15 activity could potentially reverse these detrimental effects through improved mitochondrial quality control.

Future therapeutic strategies may involve combinatorial approaches targeting both MAPK15 expression levels and phosphorylation status to maximize mitophagy induction and cellular protection against age-related stress.

What are the methodological challenges in developing phospho-MAPK15 as a biomarker for disease stratification?

Developing phospho-MAPK15 as a clinically useful biomarker presents several methodological challenges that need to be addressed through rigorous research approaches:

Methodological considerations:

• Tissue preservation optimization: Investigate phospho-epitope stability in different fixation and preservation protocols to establish standardized methods that maintain T175/Y177 phosphorylation integrity in clinical samples .

• Antibody validation for diagnostics: Expand validation of Phospho-MAPK15 (T175/Y177) antibodies to include reproducibility testing across different lots, laboratories, and detection platforms to ensure consistent stratification results .

• Quantification standardization: Develop calibrated reference standards for phospho-MAPK15 levels to enable absolute quantification rather than relative comparison, facilitating cross-study and cross-platform comparability .

• Preanalytical variable assessment: Systematically evaluate the impact of sample collection timing, processing delays, and storage conditions on phospho-MAPK15 detection to establish reliable clinical workflows .

• Multi-center clinical validation: Design prospective studies to establish phospho-MAPK15 thresholds for disease stratification, including assessment of sensitivity, specificity, and predictive value in relevant clinical contexts .

Research challenges include the intrinsically transient nature of phosphorylation modifications and potential context-dependent variability. In gastric cancer studies, phospho-MAPK15 levels correlated with copy number alterations in 17% of tumors, suggesting utility as a stratification marker for a subset of patients . Similarly, in lung cancer research, phospho-MAPK15 status predicted responsiveness to cisplatin therapies, particularly when combined with TNF-α .

The development of companion diagnostics using phospho-MAPK15 antibodies would need to address the heterogeneity observed across different cancer types and even within individual tumors. Standardization of detection methods, establishment of clinically relevant thresholds, and integration with other biomarkers into comprehensive panels would enhance the clinical utility of phospho-MAPK15 as a stratification biomarker for personalized medicine approaches.